CClinicalTrials.gg
Sign In
RecruitingNCT07665879Updated Jul 16, 2026

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

A Phase 1 interventional study of Eloralintide and Placebo in Overweight and Obesity, sponsored by Eli Lilly and Company. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 3 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.

02

Conditions studied

  • Overweight
  • Obesity

Keywords

  • Healthy
03

In context

Overweight

3,670 studies on the registry are indexed under Overweight; 849 are open to participants now.

This study's planned enrollment of 115 is above the median of 73 across 3,175 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.

Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Have an hemoglobin A1c (HbA1c) value at screening of less than 6.5 percent (%).
  • Have a body mass index between 25 and 45 Kilogram per Square Meter (kg/m²).
  • Have had a stable body weight that has changed by less than 5% during the 3 months prior to screening.
  • Are individuals assigned male at birth (AMAB) or assigned female at birth (AFAB). Individuals of childbearing potential (IOCBP) and individuals not of childbearing potential (INOCBP) may participate in this study.

Exclusion criteria

Exclusion Criteria:

  • Have type 1 or type 2 diabetes mellitus, a history of ketoacidosis, or of hyperosmolar state or coma. Note: Participants with a history of gestational diabetes are eligible to participate in this study.
  • Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis.
  • Have a known clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal (GI) motility to a significant extent.

  • Have a prior or planned surgical treatment for obesity. Exceptions: The following are allowed if they occurred more than 1 year before screening:

    • liposuction
    • cryolipolysis, or
    • abdominoplasty.
  • Are unwilling to comply with the lifestyle and dietary restrictions required for this study.
  • Are individuals AFAB who are lactating.
  • Are individuals AFAB who are pregnant or intend to become pregnant or to breastfeed during the study, or individuals AMAB who intend to conceive a pregnancy during the study.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    Eloralintide

    Eloralintide administered subcutaneously (SC)

    Drug: Eloralintide

  • Placebo comparator
    Placebo

    Placebo administered SC

    Other: Placebo

Interventions

  • DrugEloralintide

    Eloralintide administered SC

    Also known as: LY3841136

  • OtherPlacebo

    Placebo administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline In Hyperinsulinemic Euglycemic Clamp (HEC) Predicted Clamp-Derived Insulin Sensitivity (M-value)

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline In Body Weight

    Time frame: Baseline, Week 24

07

Study locations

1 of 2 sites recruiting
  • Profil Institut für Stoffwechselforschung
    Neuss, 41460, Germany
    • · Contact · 4921314018180
    • Patrick Fischer · Principal investigator
    Recruiting
  • CTC GoCo
    Mölndal, 431 53, Sweden
    • · Contact · 46317001180
    • Kaj Stenlöf · Principal investigator
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07665879
Lead sponsor
Eli Lilly and Company
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Jun 24, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Overweight→

Other studies from this sponsor

Eli Lilly and Company

Start the discussion